Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Sen. Bill Cassidy reintroduced the Treat and Reduce Obesity Act (TROA) to address the obesity crisis through Medicare ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

They have been called miraculous and the fastest way to lose weight. From Wegovy to Mounjaro, here’s how GLP-1 drugs work ...

Novo Nordisk is making a strategic push into India's weight-loss market to secure its position ahead of competition from ...

The CDC stopped recommending Covid shots for healthy children and pregnant women, while Hinge Health makes its debut on the ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...